Combination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders

Clinical Neuropharmacology

Volumn 30, Issue 3, 2007, Pages 127-135

  Gerra, Gilberto ^a   Di Petta, Gilberto ^b   D'Amore, Antonio ^c   Iannotta, Pasquale ^c   Bardicchia, Francesco ^e   Falorni, Fabio ^e   Coacci, Alessandro ^e   Strepparola, Giovanni ^f   Campione, Guglielmo ^f   Lucchini, Alfio ^f   Vedda, Giuseppina ^d   Serio, Giorgio ^d   Manzato, Ezio ^g   Antonioni, Maina ^a   Bertacca, Simone ^a   Moi, Gabriele ^a   Zaimovic, Amir ^a  

^a AUSL   (Italy)

^b Dipartimento Dipendenze ASL Caserta   (Italy)

^c Dipartimento Dipendenze ASL Napoli 3   (Italy)

^d Dipartimento Dipendenze Patologiche AUSL 6 Palermo   (Italy)

^e Dipartimento Dipendenze ASL Grosseto   (Italy)

^f Dipartimento Dipendenze ASL 2   (Italy)

^g Dipartimento Dipendenze ASL Verona   (Italy)

Author keywords

Heroin dependence; Maintenance treatment; Olanzapine; Opioid agonists; Psychiatric comorbidity; Schizoaffective bipolar disorder; Schizophrenia; Schizotypal

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BUPRENORPHINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIAMORPHINE; FLUOXETINE; HALOPERIDOL; METHADONE; NALTREXONE; OLANZAPINE; OPIATE AGONIST; PAROXETINE;

ADULT; AKATHISIA; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG TOLERABILITY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; EYELID DISEASE; FEMALE; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OCULOGYRIC CRISIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RESTLESSNESS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; SIDE EFFECT; SUBSTANCE ABUSE; SYMPTOM CHECKLIST 90; TARDIVE DYSKINESIA; TORTICOLLIS; URINALYSIS; WEIGHT GAIN; WITHDRAWAL SYNDROME;

ADULT; ANALGESICS, OPIOID; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BUPRENORPHINE; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; METHADONE; MULTIVARIATE ANALYSIS; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 34249893364     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/wnf.0b013e31803354f6     Document Type: Article

References (24)

1. Levin FR, McDowell D, Evans SM, et al. Pergolide mesylate for cocaine abuse: a controlled preliminary trial. Am J Addict 1999;8(2):120-127.
2. Rubio G, Jimenez-Arriero MA, Ponce G, et al. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol 2001;36(5):419-425.
3. Bano MD, Agujetas M, Lopez ML, et al. Fluoxetine (FX) efficacy in the treatment of cocaine dependence methadone maintenance patients. Interaction with plasma levels. Actas Esp Psiquiatr 1999;27(5):321-324.
4. Levin FR, Evans SM, McDowell DM, et al. Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder. J Addict Dis 2002;21(2):1-16.
5. Ziedonis DM. Integrated treatment of co-occurring mental illness and addiction: clinical intervention, program, and system perspectives. CNS Spectr 2004;9(12):892-904. 925.
6. Petrakis I, Carroll KM, Nich C, et al. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug Alcohol Depend 1998;50(3):221-226.
7. Schmitz JM, Averill P, Stotts AL, et al. Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug Alcohol Depend 2001;63(3):207-214.
8. Green AI, Zimmet SV, Strous RD, et al. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry 1999;6(6):287-296.
9. Fava M, Mulroy R, Alpert J, et al. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry 1997;154(12):1760-1762.
10. Sattar SP, Bhatia SC, Petty F. Potential benefits of quetiapine in the treatment of substance dependence disorders. J Psychiatry Neurosci 2004;29(6):452-457.
11. Westerink BH, Kawahara Y, De Boer P, et al. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur J Pharmacol 2001;412(2):127-138.
12. Spitzer RL, Williams JBW, Gibbon M, et al. Structured Clinical Interview According to DSM-III-R. Washington, DC and London, England: American Psychiatric Press, 1990.
13. Fava M, Guaraldi GB, Mazzi F, et al. Intervista Clinica Strutturata per il DSM-III-R. Florence, Italy: Organizzazioni Speciali; 1993.
14. Maffei C, Fossati A, Agostini I, et al. Interrater reliability and internal consistency of the structured clinical interview for DSM-IV axis II personality disorders (SCID-II), version 2.0. J Personal Disord 1997;11(3):279-284.
15. Derogatis LR. SCL-90-R: Administration, Scoring and Procedure Manual - II. Baltimore, MD: Clinical Psychometric Research; 1992.
16. Gerra G, Borella F, Zaimovic A, et al. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend 2004;75(1):37-45.
17. Gerra G, Leonardi C, D'Amore A, et al. Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: a retrospective study. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:265-272.
18. McEvoy JP, Freudenreich O, Levin ED, et al. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology (Berl) 1995;119(1):124-126.
19. Drake RE, Xie H, McHugo GJ, et al. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000;26(2):441-449.
20. Casey DE. Antipsychotics standard of care redefining the definition of atypical antipsychotics. J Clin Psychiatry 2000;61(suppl 3):3.
21. Tsuang JW, Eckman TE, Shaner A, et al. Clozapine for substance-abusing schizophrenic patients. Am J Psychiatry 1999;156(7):1119-1120.
22. Littrell KH, Petty RG, Hilligoss NM, et al. Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abuse Treat 2001;21(4):217-221.
23. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend 2003;70(3):265-273.
24. Reid MS, Casadonte P, Baker S, et al. A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence. Addiction 2005;100(suppl 1):43-57.